Valuation: Thalia Therapeutics Plc

Market Cap 11.1M 14.69M 13.12M 12.2M 20.95M 1.42B 21.05M 147M 57.54M 725M 55.15M 53.94M 2.33B P/E 2024
-1.69x
P/E 2025 -3.09x
Enterprise Value 10.02M 13.26M 11.84M 11.01M 18.92M 1.28B 19M 133M 51.94M 654M 49.79M 48.7M 2.1B EV / Sales 2024
198,657,512x
EV / Sales 2025 452,941,079x
Free-Float
41.35%
Yield 2024 *
-
Yield 2025 -
1 day-4.00%
1 week-4.00%
Current month-4.00%
1 month+9.09%
3 months-7.69%
6 months-11.11%
Current year+14.29%
1 week 0.6
Extreme 0.6
0.65
1 month 0.5
Extreme 0.5
0.65
Current year 0.4
Extreme 0.4
0.95
1 year 0.4
Extreme 0.4
0.95
3 years 0.35
Extreme 0.35
1.5
5 years 0.35
Extreme 0.35
8.69
10 years 0.35
Extreme 0.35
35.7
Manager TitleAgeSince
Chief Executive Officer 66 23/02/2026
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 56 26/05/2025
Director TitleAgeSince
Director/Board Member 48 13/07/2020
Chairman 59 31/07/2023
Director/Board Member 81 08/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
28/11/24 Free

Founder

6,000,000 1.5198%
28/11/24 Free

Director

3,000,000 0.7599%
28/11/24 Free

Chairman

3,000,000 0.7599%
Change 5-day change 1-year change 3-year change Capi.($)
-4.00%-4.00%0.00%-36.84% 14.69M
-2.59%-5.70%+50.69%+79.01% 70.61B
+0.66%-9.82%+5.02%+52.50% 51.01B
+0.30%-0.14%+8.42%+32.99% 48.1B
+0.56%-1.86%+28.15%+32.14% 42.78B
+0.66%-8.09%+291.53%+688.72% 40.67B
-0.19%-2.46%+7.86%+100.16% 40.3B
-2.13%-1.64%+8.63%+46.15% 30.59B
-2.23%-4.96%+46.01%+6.04% 28.16B
-0.27%-0.76%-5.28%-11.02% 24.36B
Average -0.92%-2.39%+44.10%+98.99% 37.66B
Weighted average by Cap. -0.61%-2.94%+50.58%+118.38%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.93 0.01 0.1 0.04 0.48 0.04 0.04 1.53 0.01 0.01 0.01 0.01 0.01 0.93 0.01 0.1 0.04 0.47 0.04 0.04 1.52
Net income -1.06M -1.4M -1.25M -1.16M -2M -136M -2.01M -14.01M -5.49M -69.12M -5.26M -5.15M -222M -1.21M -1.59M -1.42M -1.32M -2.28M -154M -2.29M -15.94M -6.25M -78.68M -5.99M -5.86M -252M
Net Debt -626K -828K -740K -688K -1.18M -80.17M -1.19M -8.28M -3.25M -40.87M -3.11M -3.04M -131M -1.08M -1.43M -1.28M -1.19M -2.04M -138M -2.05M -14.28M -5.6M -70.47M -5.36M -5.25M -226M
Projected Income Statement - Annual - Thalia Therapeutics Plc
Logo Thalia Therapeutics Plc
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
Employees
3
Date Price Change Volume
12/10/26 GBX 0.6000 -4.00% 11,768
09/10/26 GBX 0.6250 0.00% 9,116
08/10/26 GBX 0.6250 0.00% 398,165
07/10/26 GBX 0.6250 0.00% 648,882
06/10/26 GBX 0.6250 0.00% 121,919
  1. Stock Market
  2. Stocks
  3. THAT Stock